logo-loader
HealthPharma & Biotech
Allergy Therapeutics PLC

Allergy Therapeutics surprised by the results of PQ Birch jab trial

The B301 trial was a multi-centre, double-blind, placebo-controlled study designed to test the efficacy in birch-pollen induced seasonal allergic rhinitis

Birch trees
The group will undertake a review of the full trial dataset to understand any cause for the lack of consistency in the clinical outcomes seen between the studies

Allergy Therapeutics PLC (LON:AGY) received a setback as top-line results from the Phase III clinical trial of its new adjuvanted birch allergoid product disappointed.

The profitable drugs development company said the trial did not show a statistically significant difference between those taking the drug and those receiving the placebo.

READ: Allergy Therapeutics sees first-half sales, profits jump ahead of “pivotal” year

The safety and tolerability profile was positive and consistent with that observed in previous trials and the company stressed that secondary endpoint analyses of immunoglobulin markers, including the IgG and IgG4 sub-class results, showed highly statistically significant differences between active and placebo, suggesting a strong and sustained immune response to treatment.

"We are surprised by the result, given the strong immune response suggested by the increased immunoglobulin markers in the treatment arm and the substantial symptom improvement we had observed in earlier trials,” said Manuel Llobet, the chief executive officer at Allergy Therapeutics.

“We will now undertake a comprehensive review of the full dataset to determine our path forward with the investigational product. As a science-driven company, we are conscious at Allergy Therapeutics of the challenges regarding subjective measures in allergy field studies. We are committed to overcoming these challenges and bringing this new product to market," he added.

Quick facts: Allergy Therapeutics PLC

Price: £0.12

Market: AIM
Market Cap: £78.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read